Senescent cells targeted with new nanocarrier drug delivery system
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
List view / Grid view
Senescent, or zombie cells, are being targeted with the development of a new nanocarrier drug delivery system.
Saliva has been used to measure stress hormones, enzyme levels and cancer mutations...
Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy...
Novel biomarker identified those with improved progression-free and overall survival...
Supports development of analytical workflows to generate precise molecular profiles of patients...
A test that analyses free-floating DNA in the blood may be able to detect early-stage lung cancer...
Researchers have developed a highly specific apoptosis assay designed for immunofluorescence microscopy analysis of fixed core needle biopsy specimens...
Machine learning has detected one of the commonest causes of dementia and stroke, in the most widely used form of brain scan (CT), more accurately than current methods.
A new blood test has been found to more accurately predict the development of tuberculosis up to two years before its onset in people living with someone with active TB...
New research highlights effective methods for identifying a common side effect in children receiving drug treatments for Cystic fibrosis...
Scientists have developed and validated a blood test for Alzheimer’s disease, with the potential to massively ramp up the pace of Alzheimer’s disease drug trials...
Much rests on the further development of bioanalytical technologies which allow the highest level of sensitivity on small samples, and robust, high reproducibility across large populations. Johan Devenyns, CEO PharmaFluidics, explains further...
Taxanes inhibit cell division and make cancer cells sensitive to radiation therapy, a current study has investigated the underlying mechanisms of this action...
The FDA has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) to treat patients with metastatic non-small cell lung cancer.
European Pharmaceutical Review, Issue 2 of 2016 focused on nanotechnology and stem cell technology to monitor glucose and prevent diabetes, respectively. The aim of this review is to sensitise the technology innovators in this field by providing expert opinions on biomedical products and technologies that have come the closest so…